Tandem Diabetes Care (NASDAQ:TNDM) Posts Earnings Results, Beats Estimates By $0.15 EPS

Tandem Diabetes Care (NASDAQ:TNDM) posted its quarterly earnings results on Thursday. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.15, FiscalAI reports. The business had revenue of $283.69 million for the quarter, compared to the consensus estimate of $265.85 million. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Q3 results were strong: worldwide revenue rose 14% to $284 million and pump shipments increased 12%, while gross margin reached 57% and adjusted EBITDA margin was 6%. Tandem maintained its 2026 sales guidance of $1.065 billion–$1.085 billion.
• Pharmacy adoption is progressing more slowly than expected, though formulary coverage reached about 50% and recurring supply economics exceeded baseline expectations. Tandem expects the transition to weigh on sales into 2027 and said mid- to high-single-digit revenue growth is a reasonable starting point for next year.
• International sales rose 26% to a record $93 million, supported by product launches and stronger direct-market performance. Tandem plans to expand direct operations to cover roughly half of its international installed base by the end of 2027.
• Product development could broaden Tandem’s market opportunity: Mobi Tubeless is in late-stage FDA review, with commercial availability targeted for the first half of 2027 if cleared. The company also plans to begin a pivotal trial of its fully closed-loop system by year-end 2026, with a potential launch in 2028.

Tandem Diabetes Care Stock Down 5.6%

Shares of NASDAQ TNDM traded down $1.06 during mid-day trading on Thursday, reaching $17.99. 3,017,671 shares of the company were exchanged, compared to its average volume of 2,138,888. The company has a quick ratio of 2.65, a current ratio of 3.18 and a debt-to-equity ratio of 4.62. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -19.34 and a beta of 1.59. Tandem Diabetes Care has a 1 year low of $12.26 and a 1 year high of $29.65. The firm has a 50-day moving average of $17.81 and a 200 day moving average of $18.91.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TNDM shares. UBS Group initiated coverage on Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price objective for the company. Royal Bank Of Canada restated an “outperform” rating and issued a $26.00 price target (down from $30.00) on shares of Tandem Diabetes Care in a report on Friday, August 7th. Oppenheimer reaffirmed an “outperform” rating on shares of Tandem Diabetes Care in a research report on Friday, August 7th. Citigroup lowered their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $27.08.

Insiders Place Their Bets

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the transaction, the director owned 24,434 shares in the company, valued at $467,911.10. The trade was a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.